CN114617982A - 一种神经内分泌肿瘤靶向的纳米粒子制备方法 - Google Patents

一种神经内分泌肿瘤靶向的纳米粒子制备方法 Download PDF

Info

Publication number
CN114617982A
CN114617982A CN202210290899.XA CN202210290899A CN114617982A CN 114617982 A CN114617982 A CN 114617982A CN 202210290899 A CN202210290899 A CN 202210290899A CN 114617982 A CN114617982 A CN 114617982A
Authority
CN
China
Prior art keywords
neuroendocrine tumor
nano
preparing
steps
following
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210290899.XA
Other languages
English (en)
Inventor
肖松涛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Health Qihang Technology Co ltd
Original Assignee
Beijing Health Qihang Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Health Qihang Technology Co ltd filed Critical Beijing Health Qihang Technology Co ltd
Priority to CN202210290899.XA priority Critical patent/CN114617982A/zh
Publication of CN114617982A publication Critical patent/CN114617982A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
    • A61K49/1839—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a lipid, a fatty acid having 8 or more carbon atoms in the main chain, or a phospholipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1866—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle the nanoparticle having a (super)(para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

本发明公开了一种神经内分泌肿瘤靶向的纳米粒子制备方法，将铁液，置于带夹套的1L玻璃反应釜中，采用SGC500高速剪切机恒温搅拌，30min后，用去离子水洗涤，得到表面包覆油酸钠的纳米Fe3O4粒子；将表面包覆油酸钠的纳米Fe3O4粒子配制成50mL、固含量为10g/L的Fe3O4悬浮液，加入50mL葡聚糖水溶液于烧瓶中搅拌反应；抽滤洗涤后得到双层包覆的纳米Fe3O4；将S3得到的双层包覆的纳米Fe3O4重新分散于5O mL去离子水中，加入等体积的高碘酸钠溶液，超滤清洗后加入多肽分子，得到最初产物。本发明所述的一种神经内分泌肿瘤靶向的纳米粒子制备方法，具有工艺条件简单，粒径易控等特点，实现肿瘤的靶向分子影像诊断目的，达到肿瘤早发现、早诊断、早治疗的目标。

Description

一种神经内分泌肿瘤靶向的纳米粒子制备方法
技术领域
本发明涉及放射性药物化学和临床核医学技术领域，特别涉及一种神经内分泌肿瘤靶向的纳米粒子制备方法。
背景技术
神经内分泌肿瘤(neuroendocrine tumours,NETs)，是来源于神经内分泌细胞一大类肿瘤，多发生于消化系统，但可散在发生于人体其它多个器官。在过去30年间，NETs的发病率提高约5倍。超过60％的神经内分泌肿瘤患者诊断时已处于晚期。影像检查常在NET的初始诊断和后期的病情监测中非常关键。初始的目的包括鉴别原发肿瘤、评估疾病的范围和制定治疗计划。后期的影像检查目的主要是手术后或治疗后疾病稳定期的监测，或疗效评估。敏感、准确、特异性的NET靶向探针是进行影像学检查的关键。故此，我们提出了一种神经内分泌肿瘤靶向的纳米粒子制备方法。
发明内容
本发明的主要目的在于提供一种神经内分泌肿瘤靶向的纳米粒子制备方法，可以有效解决背景技术中的问题。
为实现上述目的，本发明采取的技术方案为：
一种神经内分泌肿瘤靶向的纳米粒子制备方法，包括以下步骤：
S1：将铁液，置于带夹套的1L玻璃反应釜中，采用SGC500高速剪切机恒温搅拌，30min后，用去离子水洗涤，得到表面包覆油酸钠的纳米Fe3O4粒子；
S2：将表面包覆油酸钠的纳米Fe3O4粒子配制成50mL、固含量为10g/L的Fe3O4悬浮液，加入50mL葡聚糖水溶液于烧瓶中搅拌反应；
S3：抽滤洗涤后得到双层包覆的纳米Fe3O4；
S4：将S3得到的双层包覆的纳米Fe3O4重新分散于5O mL去离子水中，加入等体积的高碘酸钠溶液，超滤清洗后加入多肽分子，得到最初产物，即神经内分泌肿瘤靶向的纳米粒子。
优选的，在所述S1中，所述铁液为FeC12、FeC13、油酸钠的混合液。
优选的，在所述S1中，所述SGC500高速剪切机的搅拌速度为6000-8000r/min。
优选的，在所述S1中，所述铁液应满足以下条件中的至少一个：
n(Fe^2+)/n(Fe^3+)＝1.75和NaOH溶液(碱比R＝n(OH一)/n(Fe^2+Fe^3+)＝1.75)。
优选的，在所述S2中，所述葡聚糖水溶液的质量浓度为35g/L。
优选的，在所述S2中，在80-90℃下搅拌40min，搅拌速度为1200-1800r/min。
优选的，在所述S4中，所述高碘酸钠溶液的浓度为0.1mol/L。
优选的，在所述S4中，在加入多肽分子后，需要在37℃下，孵化12h。
与现有技术相比，本发明具有如下有益效果：
1、本发明通过采用共沉淀法制备磁性纳米粒子，具有工艺条件简单，粒径易控等特点，操作简便，制备得到的神经内分泌肿瘤靶向的纳米粒子可自由透过体内毛细血管壁间缝隙，大幅减少网状内皮系统摄取，从而有效地进入实体靶器官，具有较好的X射线衰减能力，能够应用于X线CT成像造影剂。
2、在本发明中，以油酸钠为包覆剂，制备了窄粒径分布的纳米Fe3O4粒子，使纳米Fe3O4粒子的平均粒径为8nm，为单畴晶磁性颗粒，具有超顺磁性，且通过加入多肽分子制成神经内分泌肿瘤靶向的纳米粒子，可以作为磁共振造影剂，在肿瘤部位浓聚效果是生理盐水的2.13倍，实现肿瘤的靶向分子影像诊断目的，达到肿瘤早发现、早诊断、早治疗的目标。
附图说明
图1为本发明一种神经内分泌肿瘤靶向的纳米粒子制备方法的流程图
具体实施方式
为使本发明实现的技术手段、创作特征、达成目的与功效易于明白了解，下面结合具体实施方式，进一步阐述本发明。
在本发明的描述中，需要说明的是，术语“上”、“下”、“内”、“外”“前端”、“后端”、“两端”、“一端”、“另一端”等指示的方位或位置关系为基于附图所示的方位或位置关系，仅是为了便于描述本发明和简化描述，而不是指示或暗示所指的装置或元件必须具有特定的方位、以特定的方位构造和操作，因此不能理解为对本发明的限制。此外，术语“第一”、“第二”仅用于描述目的，而不能理解为指示或暗示相对重要性。
在本发明的描述中，需要说明的是，除非另有明确的规定和限定，术语“安装”、“设置有”、“连接”等，应做广义理解，例如“连接”，可以是固定连接，也可以是可拆卸连接，或一体地连接；可以是机械连接，也可以是电连接；可以是直接相连，也可以通过中间媒介间接相连，可以是两个元件内部的连通。对于本领域的普通技术人员而言，可以具体情况理解上述术语在本发明中的具体含义。
实施例
一种神经内分泌肿瘤靶向的纳米粒子制备方法，由图1所示，包括以下步骤：
S1：将铁液，置于带夹套的1L玻璃反应釜中，采用SGC500高速剪切机恒温搅拌，30min后，用去离子水洗涤，得到表面包覆油酸钠的纳米Fe3O4粒子，铁液为FeC12、FeC13、油酸钠的混合液，铁液应满足以下条件中的至少一个：n(Fe^2+)/n(Fe^3+)＝1.75和NaOH溶液(碱比R＝n(OH一)/n(Fe^2+Fe^3+)＝1.75)，SGC500高速剪切机的搅拌速度为6000-8000r/min，采用高速剪切机搅拌制备的纳米Fe3O4粒子粒径分布均一，大小为8nm左右，可自由透过体内毛细血管壁间缝隙，大幅减少网状内皮系统摄取，从而有效地进入实体靶器官，具有较好的X射线衰减能力，能够应用于X线CT成像造影剂；
S2：将表面包覆油酸钠的纳米Fe3O4粒子配制成50mL、固含量为10g/L的Fe3O4悬浮液，加入50mL葡聚糖水溶液于烧瓶中搅拌反应，葡聚糖水溶液的质量浓度为35g/L，在80-90℃下搅拌40min，搅拌速度为1200-1800r/min；
S3：抽滤洗涤后得到双层包覆的纳米Fe3O4；
S4：将S3得到的双层包覆的纳米Fe3O4重新分散于5O mL去离子水中，加入等体积的高碘酸钠溶液，超滤清洗后加入多肽分子，得到最初产物，即神经内分泌肿瘤靶向的纳米粒子；高碘酸钠溶液的浓度为0.1mol/L，在加入多肽分子后，需要在37℃下，孵化12h，神经内分泌肿瘤靶向的纳米粒子可以作为磁共振造影剂，在肿瘤部位浓聚效果是生理盐水的2.13倍，实现肿瘤的靶向分子影像诊断目的，达到肿瘤早发现、早诊断、早治疗的目标。
在本发明中，以油酸钠为包覆剂，制备了窄粒径分布的纳米Fe3O4粒子，使纳米Fe3O4粒子的平均粒径为8nm，为单畴晶磁性颗粒，具有超顺磁性，且通过加入多肽分子制成神经内分泌肿瘤靶向的纳米粒子，可以作为磁共振造影剂，在肿瘤部位浓聚效果是生理盐水的2.13倍，实现肿瘤的靶向分子影像诊断目的，达到肿瘤早发现、早诊断、早治疗的目标，通过采用共沉淀法制备磁性纳米粒子，具有工艺条件简单，粒径易控等特点，操作简便，制备得到的神经内分泌肿瘤靶向的纳米粒子可自由透过体内毛细血管壁间缝隙，大幅减少网状内皮系统摄取，从而有效地进入实体靶器官，具有较好的X射线衰减能力，能够应用于X线CT成像造影剂。
以上显示和描述了本发明的基本原理和主要特征和本发明的优点。本行业的技术人员应该了解，本发明不受上述实施例的限制，上述实施例和说明书中描述的只是说明本发明的原理，在不脱离本发明精神和范围的前提下，本发明还会有各种变化和改进，这些变化和改进都落入要求保护的本发明范围内。本发明要求保护范围由所附的权利要求书及其等效物界定。

Claims (8)

1.一种神经内分泌肿瘤靶向的纳米粒子制备方法，其特征在于：包括以下步骤：
S1：将铁液，置于带夹套的1L玻璃反应釜中，采用SGC500高速剪切机恒温搅拌，30min后，用去离子水洗涤，得到表面包覆油酸钠的纳米Fe3O4粒子；
S2：将表面包覆油酸钠的纳米Fe3O4粒子配制成50mL、固含量为10g/L的Fe3O4悬浮液，加入50mL葡聚糖水溶液于烧瓶中搅拌反应；
S3：抽滤洗涤后得到双层包覆的纳米Fe3O4；
S4：将S3得到的双层包覆的纳米Fe3O4重新分散于5O mL去离子水中，加入等体积的高碘酸钠溶液，超滤清洗后加入多肽分子，得到最初产物，即神经内分泌肿瘤靶向的纳米粒子。
2.根据权利要求1所述的一种神经内分泌肿瘤靶向的纳米粒子制备方法，其特征在于：在所述S1中，所述铁液为FeC12、FeC13、油酸钠的混合液。
3.根据权利要求1所述的一种神经内分泌肿瘤靶向的纳米粒子制备方法，其特征在于：在所述S1中，所述SGC500高速剪切机的搅拌速度为6000-8000r/min。
4.根据权利要求1所述的一种神经内分泌肿瘤靶向的纳米粒子制备方法，其特征在于：在所述S1中，所述铁液应满足以下条件中的至少一个：
n(Fe^2+)/n(Fe^3+)＝1.75和NaOH溶液(碱比R＝n(OH一)/n(Fe^2+Fe^3+)＝1.75)。
5.根据权利要求1所述的一种神经内分泌肿瘤靶向的纳米粒子制备方法，其特征在于：在所述S2中，所述葡聚糖水溶液的质量浓度为35g/L。
6.根据权利要求1所述的一种神经内分泌肿瘤靶向的纳米粒子制备方法，其特征在于：在所述S2中，在80-90℃下搅拌40min，搅拌速度为1200-1800r/min。
7.根据权利要求1所述的一种神经内分泌肿瘤靶向的纳米粒子制备方法，其特征在于：在所述S4中，所述高碘酸钠溶液的浓度为0.1mol/L。
8.根据权利要求1所述的一种神经内分泌肿瘤靶向的纳米粒子制备方法，其特征在于：在所述S4中，在加入多肽分子后，需要在37℃下，孵化12h。
CN202210290899.XA 2022-03-23 2022-03-23 一种神经内分泌肿瘤靶向的纳米粒子制备方法 Pending CN114617982A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210290899.XA CN114617982A (zh) 2022-03-23 2022-03-23 一种神经内分泌肿瘤靶向的纳米粒子制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210290899.XA CN114617982A (zh) 2022-03-23 2022-03-23 一种神经内分泌肿瘤靶向的纳米粒子制备方法

Publications (1)

Publication Number Publication Date
CN114617982A true CN114617982A (zh) 2022-06-14

Family

ID=81903632

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210290899.XA Pending CN114617982A (zh) 2022-03-23 2022-03-23 一种神经内分泌肿瘤靶向的纳米粒子制备方法

Country Status (1)

Country Link
CN (1) CN114617982A (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102397565A (zh) * 2011-11-02 2012-04-04 上海市肺科医院 一种靶向-葡聚糖-uspio 复合粒子及其制造方法和应用
CN107899027A (zh) * 2017-11-07 2018-04-13 北京肿瘤医院 神经内分泌肿瘤靶向纳米粒子显像剂及其制备方法与应用
CN108287234A (zh) * 2017-03-22 2018-07-17 广东顺德工业设计研究院(广东顺德创新设计研究院) 纳米免疫磁珠及其制备方法和应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102397565A (zh) * 2011-11-02 2012-04-04 上海市肺科医院 一种靶向-葡聚糖-uspio 复合粒子及其制造方法和应用
CN108287234A (zh) * 2017-03-22 2018-07-17 广东顺德工业设计研究院(广东顺德创新设计研究院) 纳米免疫磁珠及其制备方法和应用
CN107899027A (zh) * 2017-11-07 2018-04-13 北京肿瘤医院 神经内分泌肿瘤靶向纳米粒子显像剂及其制备方法与应用

Similar Documents

Publication Publication Date Title
Shen et al. Iron oxide nanoparticle based contrast agents for magnetic resonance imaging
Tian et al. Poly (acrylic acid) bridged gadolinium metal–organic framework–gold nanoparticle composites as contrast agents for computed tomography and magnetic resonance bimodal imaging
WO2021190573A1 (zh) 一种磁性纳米复合材料及其制备方法与应用
Hu et al. Facile synthesis of hyaluronic acid-modified Fe 3 O 4/Au composite nanoparticles for targeted dual mode MR/CT imaging of tumors
CN107551279B (zh) 具有近红外光热效应和多模态成像功能的超小蛋白复合纳米粒及其制备方法和应用
JP5951769B2 (ja) 単糖類リン酸又はその誘導体で表面改質された親水性ナノ粒子、そのコロイド溶液及びその用途
Fu et al. Facile preparation of uniform FeSe 2 nanoparticles for PA/MR dual-modal imaging and photothermal cancer therapy
Liu et al. Stable gadolinium based nanoscale lyophilized injection for enhanced MR angiography with efficient renal clearance
EP2922577B1 (en) Superparamagnetic iron oxide nanoparticles with ultra-thin polymer layers
CN103041407B (zh) 核-壳型纳米造影剂、其制备方法及应用
CN103143043A (zh) 一种Fe3O4/Au复合纳米颗粒的制备方法
CN104689346B (zh) 用于肿瘤mri/ct成像和光热治疗的多功能纳米探针及应用
CN111358964A (zh) 磁性八面体铂掺杂金纳米壳、其制备方法和应用
Zhang et al. Green synthesis of sub‐10 nm gadolinium‐based nanoparticles for sparkling kidneys, tumor, and angiogenesis of tumor‐bearing mice in magnetic resonance imaging
CN103041408A (zh) 核-壳型纳米造影剂、其制备方法及应用
JP2015519302A (ja) 磁性ナノ粒子分散剤、その調製及び診断及び治療用途
Liu et al. Colloidally stabilized magnetic carbon nanotubes providing MRI contrast in mouse liver tumors
Geraldes et al. MRI contrast agents in glycobiology
CN109125744B (zh) 一种具有mri与ct双模态成像功能的钆掺杂氧化铪纳米颗粒的制备方法
CN114617982A (zh) 一种神经内分泌肿瘤靶向的纳米粒子制备方法
Yan et al. Folic acid-conjugated CuFeSe2 Nanoparticles for Targeted T2-weighted magnetic resonance imaging and computed tomography of tumors in vivo
JP2014156411A (ja) 複合磁性微粒子粉末、分散体
CN101987202A (zh) Ct造影功能的树状大分子/金-银合金纳米颗粒的制备
Lai et al. Gadolinium-chelate functionalized magnetic CuFeSe2 ternary nanocrystals for T1-T2 dual MRI and CT imaging in vitro and in vivo
JPH10120597A (ja) リンパ節高集積性コロイド粒子

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination